1. Home
  2. IONS
  3. IONS News

Latest Ionis Pharmaceuticals Inc. (IONS) News on November 18, 2025

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,100,385, According to a Recent SEC Filing

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,793,744, According to a Recent SEC Filing

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Insider Sold Shares Worth $4,377,054, According to a Recent SEC Filing

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,020,210, According to a Recent SEC Filing

Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results
IONS

Insider Monkey

2 months ago

Ionis (IONS) Price Target Hiked Following Positive Zilganersen Trial Results

Ionis to host investors and analysts for Innovation Day 2025
IONS

Business Wire

2 months ago

Ionis to host investors and analysts for Innovation Day 2025

Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe Hypertriglyceridemia – Has the Bull Case Changed?
IONS

Simply Wall St.

2 months ago

Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe Hypertriglyceridemia – Has the Bull Case Changed?

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $5,396,843, According to a Recent SEC Filing

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $2,301,264, According to a Recent SEC Filing

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,946,220, According to a Recent SEC Filing

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,195,421, According to a Recent SEC Filing

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $1,018,298, According to a Recent SEC Filing

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $12,294,703, According to a Recent SEC Filing

IONS

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Friday

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
IONS

Benzinga

3 months ago

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

IONS

MT Newswires

3 months ago

Ionis Pharmaceuticals Says Hereditary Angioedema Therapy Approved by US FDA

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
IONS

Business Wire

3 months ago

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
IONS

Insider Monkey

5 months ago

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
IONS

GlobeNewswire

5 months ago

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Can Biogen Save Even More Kids With This New Drug?
IONS

Investor's Business Daily

5 months ago

Can Biogen Save Even More Kids With This New Drug?

IONS

MT Newswires

5 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
IONS

Business Wire

5 months ago

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
IONS

Investor's Business Daily

5 months ago

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
IONS

GlobeNewswire

5 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
IONS

Insider Monkey

5 months ago

First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
IONS

Insider Monkey

5 months ago

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
IONS

Business Wire

5 months ago

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

Ionis doses first subject in Phase III trial of Angelman syndrome therapy
IONS

Clinical Trials Arena

5 months ago

Ionis doses first subject in Phase III trial of Angelman syndrome therapy

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
IONS

Business Wire

5 months ago

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
IONS

Zacks

5 months ago

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
IONS

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

This week in Trumponomics: Too bad TACO isn’t true
IONS

Yahoo Finance

6 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right
IONS

The Guardian

6 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
IONS

Yahoo Finance Video

6 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says
IONS

Reuters

6 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
IONS

USA TODAY

6 months ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
IONS

Simply Wall St.

6 months ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"
IONS

CBS News Videos

6 months ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate
IONS

Simply Wall St.

6 months ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
IONS

Zacks

6 months ago

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Ionis reports success in olezarsen trial for high triglycerides
IONS

Clinical Trials Arena

6 months ago

Ionis reports success in olezarsen trial for high triglycerides

Ionis reports positive data from study of olezarsen for hypertriglyceridemia
IONS

Clinical Trials Arena

6 months ago

Ionis reports positive data from study of olezarsen for hypertriglyceridemia

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
IONS

Zacks

6 months ago

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

IONS

MT Newswires

6 months ago

Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
IONS

Business Wire

6 months ago

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential
IONS

Insider Monkey

6 months ago

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Ionis to host 2025 virtual Annual Meeting of Stockholders
IONS

Business Wire

6 months ago

Ionis to host 2025 virtual Annual Meeting of Stockholders

IONS

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 05/05/2025

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts
IONS

Simply Wall St.

6 months ago

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations
IONS

Simply Wall St.

7 months ago

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

IONS

Morningstar Research

7 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

IONS

MT Newswires

7 months ago

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
IONS

Zacks

7 months ago

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
IONS

GuruFocus.com

7 months ago

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

IONS

Thomson Reuters StreetEvents

7 months ago

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
IONS

Zacks

7 months ago

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

IONS

MT Newswires

7 months ago

Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
IONS

Zacks

7 months ago

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

IONS

Associated Press Finance

7 months ago

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis reports first quarter 2025 financial results
IONS

Business Wire

7 months ago

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
IONS

Business Wire

7 months ago

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
IONS

Zacks

7 months ago

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
IONS

Zacks

7 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis to hold first quarter 2025 financial results webcast
IONS

Business Wire

7 months ago

Ionis to hold first quarter 2025 financial results webcast

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
IONS

Zacks

7 months ago

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

IONS

MT Newswires

7 months ago

HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target

Ionis to host expert panel discussion on sHTG
IONS

Business Wire

7 months ago

Ionis to host expert panel discussion on sHTG

IONS

MT Newswires

8 months ago

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target

Ionis to present at upcoming investor conferences
IONS

Business Wire

8 months ago

Ionis to present at upcoming investor conferences

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
IONS

Zacks

8 months ago

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Ionis and Sobi agree on olezarsen commercialisation
IONS

Pharmaceutical Technology

8 months ago

Ionis and Sobi agree on olezarsen commercialisation

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
IONS

Zacks

8 months ago

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

IONS

MT Newswires

8 months ago

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
IONS

Business Wire

8 months ago

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts
IONS

Insider Monkey

8 months ago

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
IONS

Zacks

8 months ago

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

Ono earmarks $940m to gain rare blood cancer therapy from Ionis
IONS

Pharmaceutical Technology

8 months ago

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
IONS

Benzinga

8 months ago

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
IONS

Zacks

8 months ago

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono

Ono pays $280M to license Ionis rare disease drug
IONS

BioPharma Dive

8 months ago

Ono pays $280M to license Ionis rare disease drug

IONS

MT Newswires

8 months ago

Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
IONS

Business Wire

8 months ago

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
IONS

Zacks

8 months ago

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

IONS

MT Newswires

8 months ago

Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
IONS

Business Wire

8 months ago

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...
IONS

GuruFocus.com

9 months ago

Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...

Ionis to present at upcoming investor conferences
IONS

Business Wire

9 months ago

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James
IONS

TipRanks

9 months ago

Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James

Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now
IONS

Insider Monkey

9 months ago

Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
IONS

Zacks

9 months ago

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus

IONS

Morningstar Research

9 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
IONS

Business Wire

9 months ago

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
IONS

Simply Wall St.

9 months ago

Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

IONS

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...
IONS

GuruFocus.com

9 months ago

Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
IONS

Benzinga

9 months ago

Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales

Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
IONS

Zacks

9 months ago

Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
IONS

Zacks

9 months ago

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

IONS

MT Newswires

9 months ago

Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set

IONS

Associated Press Finance

9 months ago

Ionis Pharmaceuticals: Q4 Earnings Snapshot

Share on Social Networks: